Financials data is unavailable for this security.
Cash flow in SEKView more
In 2024, XSpray Pharma AB (publ) increased its cash reserves by 25.21%, or 41.93m. Cash Flow from Financing totalled 306.11m or -- of revenues. In addition the company used 222.37m for operations while cash used for investing totalled 42.14m.
| Cash flow per share | -5.71 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 15.37 |
|---|---|
| Tangible book value per share | 3.16 |
More ▼
Balance sheet in SEKView more
| Current ratio | 6.72 |
|---|---|
| Quick ratio | 5.93 |
| Total debt/total equity | 0.232 |
|---|---|
| Total debt/total capital | 0.1883 |
More ▼
